CEO Executive AssistantThe commercial team in a pharmaceutical company is where product value translates into revenue. For a pharma CEO, particularly one who has a commercial background, the temptation to stay closely involved in commercial operations, reviewing sales force deployment plans, attending regional sales meetings, second-guessing promotional campaign choices, or managing key account relationships directly, is significant.
But the commercial team that operates under constant CEO oversight is a commercial team that is learning to wait for CEO guidance rather than developing its own commercial judgment. Over time, this pattern produces a commercial organization that is slower, less adaptive, and less capable than it should be, because the CEO’s involvement has substituted for the team’s development rather than accelerating it.
These practical tips help pharma CEOs find the right level of commercial engagement: visible enough to drive organizational energy, bounded enough to allow the commercial team to develop genuine capability and accountability.
Tip 1: Make the CCO the Single Accountable Owner for Commercial Results
The most important structural tip is ensuring that commercial accountability is unambiguously held by one person: the Chief Commercial Officer. When commercial accountability is diffuse, with the CEO, the CCO, and potentially other functional leaders all sharing ownership of commercial outcomes, decision-making slows and accountability evaporates.
Define clearly: the CCO is accountable for commercial results. Full stop. This means the CEO evaluates the CCO on commercial performance (revenue, market share, payer access) and then holds the CCO accountable for addressing commercial shortfalls, not personally solving them.
This single accountable owner structure sounds simple but requires CEO discipline to maintain. When commercial results disappoint, the natural tendency is for the CEO to step in. The appropriate response is to hold the CCO accountable for a credible response plan and provide backing for that plan, not to take over commercial management.
Tip 2: Review Commercial Performance, Do Not Manage It
Design your commercial engagement to be performance review rather than performance management. This is a meaningful distinction:
Performance review: The CEO reviews commercial metrics, understands trends, asks strategic questions, and makes decisions about resource allocation or strategic direction when needed. This is appropriate CEO engagement.
Performance management: The CEO reviews individual sales representative performance, attends territory-level planning meetings, approves tactical promotional decisions, or weighs in on individual customer situations. This is over-involvement that belongs to the commercial management structure.
Maintain the discipline to stay in performance review mode. When you find yourself being pulled into performance management territory, ask whether the CCO and the commercial management structure should be handling this and why it has reached you.
Tip 3: Design Your Commercial Dashboard for Strategic Visibility
Work with the CCO to design a commercial dashboard that gives you strategic visibility in a 20-minute weekly review. The dashboard should tell you: whether the business is on track, where the primary risks are, and whether any strategic decisions are needed. It should not require you to dig for information or manage through data directly.
Essential elements: net revenue versus forecast with trend, prescription share versus target, key payer coverage status, sales force performance summary (are they reaching target customers at target frequency), and competitive landscape summary. One-sentence CCO commentary on any red indicator.
If you find yourself regularly requesting additional data beyond the dashboard to understand what is happening in the commercial business, the dashboard is not well designed. Work with the CCO to improve it rather than managing through more frequent ad hoc requests.
Tip 4: Trust the Sales Force Management Structure
The CEO who conducts field rides, attends regional sales meetings, or communicates directly with district managers is working around the commercial management structure. This behavior, however well-intentioned, sends the signal that the CEO does not trust the commercial managers to manage effectively.
Engage with the commercial field through structured mechanisms: participate in the national sales meeting as a keynote and culture-setting presence, conduct one or two annual field rides to calibrate your market understanding (coordinated through the CCO), and receive a commercial field intelligence summary prepared by the CCO rather than gathering it yourself.
These bounded engagements provide genuine commercial insight without substituting for the commercial management structure.
Tip 5: Let the CCO Own Promotional Strategy
Promotional strategy, including the brand positioning, messaging architecture, campaign design, and media mix, should be owned by the CCO and the commercial marketing organization. The CEO should see and approve the overall brand strategy once per year and review significant campaign concepts before major production investments, but should not be editing copy, second-guessing creative choices, or managing promotional agency relationships.
When the CCO presents the annual brand plan, the CEO’s role is strategic: Is the positioning sustainable and differentiated? Is the resource allocation appropriate? Are the expected outcomes realistic? This is a 90-minute strategic review, not a detailed promotional review session.
For a broader view of how commercial team delegation connects to the overall pharma CEO delegation structure, see pharma CEO delegation guide, which covers how pharma CEOs can structure delegation across all commercial and R&D functions.
Tip 6: Manage Key Account Relationships Strategically
For most pharmaceutical companies, certain key accounts, the largest managed care organizations, major hospital systems, specialty pharmacy chains, and key government customers, have relationships that benefit from CEO-level engagement. But managing these relationships at a CEO level looks very different from day-to-day commercial account management.
CEO-level key account management should be: an annual or semi-annual meeting with the C-suite leadership of the most strategic accounts, where the CEO represents the company’s long-term partnership commitment and strategic direction. The CCO and Head of Market Access coordinate these meetings; the CEO attends as the organizational principal.
Day-to-day account management, including formulary negotiations, contract details, and operational problem-solving, belongs entirely to the commercial and market access teams.
Tip 7: Establish a Quarterly Commercial Strategy Review
Beyond the regular performance dashboard, a quarterly commercial strategy review with the CCO and commercial leadership team provides a deeper forum for strategic commercial questions. This 90-minute to two-hour meeting covers: strategic commercial performance against annual plan, emerging market dynamics that may require strategic response, competitive developments and their commercial implications, and any strategic commercial decisions that need CEO input.
This meeting is not a performance review repetition. It is a strategic conversation that the CEO leads, with the CCO and commercial leadership providing the analytical foundation. Prepare questions in advance; the meeting should be dialogue, not presentation.
Tip 8: Give Direct Feedback to the CCO, Not to the Commercial Team
When you have observations about commercial performance, strategy, or culture, deliver that feedback to the CCO, not to the commercial team directly. Working around the CCO to communicate feedback to the commercial organization undermines the CCO’s authority and creates confusion about who is actually running the commercial function.
This principle applies to positive feedback as well. When the commercial team achieves a significant win, celebrate it through the CCO’s channel (a commercial team communication or meeting) rather than direct CEO communication that bypasses commercial leadership.
According to McKinsey research on high-performing commercial organizations, pharmaceutical companies with strong commercial leadership operating with clear authority and CEO strategic backing consistently outperform those where commercial decision-making is diffuse or over-centralized. These tips are designed to create the CCO authority and CEO strategic backing that this research describes.
Tip 9: Connect Commercial Performance to Pipeline and Strategy
The CEO’s most distinctive contribution to commercial team leadership is connecting current commercial performance to the company’s longer-range pipeline and strategy. This strategic connection, which links the CCO’s quarterly performance results to the scientific programs that will generate future products, the regulatory decisions that will expand or constrain commercial opportunity, and the competitive dynamics that will shape the market for future launches, is uniquely the CEO’s view.
Bring this strategic perspective into commercial discussions through thoughtful questions: How do current commercial challenges inform our market access strategy for the next launch? What do we need to learn from this market to inform how we price the next product? What competitive dynamics should we be building defenses against now?
These CEO-level strategic questions add value that no commercial team member can provide from within the commercial function. They are also the best argument for keeping the CEO out of day-to-day commercial management: the CEO’s time is better spent on these connecting questions than on commercial execution detail.
See pharma drug pipeline for a framework on how pipeline management delegation connects to the commercial team delegation structure, ensuring coherent CEO oversight across both development and commercial functions.
Building a High-Delegation Commercial Culture
The tips above, applied consistently over time, build a commercial organization with genuine capability, clear accountability, and the confidence to make commercial decisions without constant CEO involvement. This is the definition of a high-delegation commercial culture, and it is the commercial organizational model that scales from a single product launch to a multi-product global portfolio.
The CEO who invests in building this culture through disciplined delegation is building an organizational asset that compounds in value with every commercial challenge the team navigates independently and every commercial success they achieve on their own initiative. That compounding capability is the true return on investment in commercial delegation.
Related Reading
For further context, explore Delegation Tips for AI Startup CEOs and Delegation Tips for Automotive CEO: Digital Teams.